16:HKEX

AS PARTNERS CO LTD

Data as of 2026-03-11 - not real-time

₩1,820.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at 1,820 KRW, modestly above the DCF‑derived fair value of 1,756.78 KRW, suggesting a slight premium. Technicals show the price sitting below the 20‑day SMA of 1,911.7 and the 200‑day SMA of 2,070.57, while the 50‑day SMA remains close at 1,901.02, indicating a neutral to bearish trend. However, the RSI of 31.3 points to oversold conditions and the recent rise in trading volume adds momentum to a potential short‑term rebound toward the resistance around 1,980 KRW. The MACD is in a bearish configuration, with the line well below the signal, tempering optimism about sustained upside. On the fundamentals side, revenue growth of 7.2% is respectable, yet profit margins are razor‑thin (0.4% net margin) and ROE is near zero, raising concerns about earnings durability. The dividend yield stands at an attractive 4.4% with a 20% payout ratio, but the lack of meaningful EPS makes the dividend’s sustainability questionable. Despite a low beta near zero and a 30‑day volatility of about 16.8%, the stock has experienced a maximum drawdown of roughly 24.8%, reflecting notable price swings. Compared with an industry average P/E of 18.2, the company’s price‑to‑sales of 0.53 appears cheap, yet the overall valuation leans toward being overvalued given the DCF gap and weak profitability. In summary, the stock presents a mixed picture: short‑term technical support and a solid dividend contrast with fundamental earnings weakness and a modest premium over intrinsic value.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • RSI in oversold territory (~31)
  • Increasing volume trend
  • Proximity to resistance level at 1,980 KRW

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Weak profitability and near‑zero ROE
  • Dividend yield attractive but sustainability doubtful
  • Price still above DCF fair value

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Overvaluation relative to DCF and industry benchmarks
  • Persistently low margins and earnings
  • Potential downside from max drawdown history (~25%)

Key Metrics & Analysis

Financial Health

Revenue Growth7.20%
Profit Margin0.40%
ROE0.00%
ROA0.25%
Debt/Equity18.81
Op. Cash Flow₩1.8B
Free Cash Flow₩1.1B
Industry P/E18.2

Technical Analysis

TrendNeutral
RSI31.3
Support₩0.00
Resistance₩1,980.00
MA 20₩1,911.70
MA 50₩1,901.02
MA 200₩2,070.57
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Fair Value₩1,756.78
GradeOvervalued
TypeValue
Dividend Yield4.40%

Risk Assessment

Beta-0.01
Volatility16.76%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.